Adverse reactions to biological modifiers

Current Opinion in Allergy and Clinical Immunology

Volumn 4, Issue 4, 2004, Pages 277-283

  Weber, Richard W ^a,b  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE   (United States)

Author keywords

Adverse reaction; Biologic modifier; Cytokine antagonist

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; DENILEUKIN DIFTITOX; ETANERCEPT; GAMMA INTERFERON; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; INFLIXIMAB; INTERFERON; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; LEFLUNOMIDE; LENERCEPT; MERCAPTOPURINE; METHOTREXATE; MONOCLONAL ANTIBODY; OKT 3; OMALIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; STEROID; THEOPHYLLINE; TUMOR NECROSIS FACTOR ANTIBODY; UNINDEXED DRUG;

ABDOMINAL ABSCESS; ACUTE CHOLECYSTITIS; ADOLESCENT; ADULT; ARTHRITIS; ASEPTIC MENINGITIS; ASTHMA; CELLULITIS; CHILD; CHRONIC GRANULOMATOUS DISEASE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CROHN DISEASE; DEMYELINATING DISEASE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG HYPERSENSITIVITY; DYSPNEA; FEMALE; FLU LIKE SYNDROME; FOLLICULITIS; GRAFT REJECTION; GRANULOMA ANNULARE; HEADACHE; HEART FAILURE; HEMATURIA; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOMODULATION; KAPOSI SARCOMA; LEUKOCYTOCLASTIC VASCULITIS; LICHENOID ERUPTION; LIVER TOXICITY; LUNG FIBROSIS; LUNG GRANULOMA; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MALAISE; MALE; MELANOMA; META ANALYSIS; MORTALITY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHOTODERMATOSIS; PNEUMONIA; PRIORITY JOURNAL; PRURITUS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RASH; RAYNAUD PHENOMENON; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SERUM SICKNESS; SIDE EFFECT; SKIN LYMPHOMA; TUBERCULOSIS; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; VIRUS INFECTION;

ANTIBODIES, MONOCLONAL; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; INTERFERONS; INTERLEUKIN-1; TUMOR NECROSIS FACTOR-ALPHA;

EID: 3442900458     PISSN: 15284050     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.all.0000136757.58818.10     Document Type: Review

References (40)

1. Nelson RP Jr, Ballow M. Immunomodulation and immunotherapy: drugs, cytokines, cytokine receptors, and antibodies. J Allergy Clin Immunol 2003; 111 (Suppl):S720-S732. An excellent review covering older modalities as well as newer biological modifiers. It provides background and rationale for treatment, and was published as part of a primer on allergic and immunological disorders.
2. Watts RA. Musculoskeletal and systemic reactions to biological therapeutic agents. Curr Opin Rheumatol 2000; 12:49-52.
3. Kälkner K-M, Rønnberg L, Karlsson Parra A, et al. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Q J Med 1998; 91:393-399.
4. Bell TM, Bansal AS, Shorthouse C, et al. Low-titre auto-antibodies predict autoimmune disease during interferon-alpha treatment of chronic hepatitis C. J Gastroenterol Hepatol 1999; 14:419-422.
5. Nikolaus S, Rutgeerts P, Fedorak R, et al. Interferon β-1a in ulcerative colitis: a placebo controlled, randomized, dose escalating study. Gut 2003; 52:1286-1290.
6. Nousari HC, Kimyai-Asadi A, Tausk F. Subacute cutaneous lupus erythematosus associated with interferon beta-1a. Lancet 1998; 352:1825-1826.
7. Festi D, Sandri L, Mazzella G, et al. Safety of interferon β treatment for chronic HCV hepatitis. World J Gastroenterol 2004; 10:12-16.
8. Colosimo C, Pozzilli C, Frontomi M, et al. No increase in serum autoantibodies during therapy with recombinant interferon-β 1 a in relapsing remitting multiple sclerosis. Acta Neurol Scand 1997; 96:372-374.
9. Bencsáth M, Blaskovits A, Borvendég J. Biomolecular cytokine therapy. Pathol Oncol Res 2003; 9:24-29. An excellent review of the impact of cytokine therapy in signaling pathways. It defines and contrasts mechanisms of action of several biological modifiers and the implications of their use.
10. Day R. Adverse reactions to TNF-α inhibitors in rheumatoid arthritis. Lancet 2002; 359:540-541.
11. Werth VP, Levinson AI. Etanercept-induced injection site reactions: mechanistic insights from clinical findings and immunohistochemistry. Arch Dermatol 2001; 137:953-955.
12. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthr Rheum 2003; 48:3230-3236.
13. Zeltser R, Valle L, Tanck C, et al. Clinical, histological, and immunophenotypic characteristics of injection site reactions associated with etanercept: a recombinant tumor necrosis factor α receptor: Fc fusion protein. Arch Dermatol 2001; 137:893-899.
14. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vascultis due to etanercept. J Rheumatol 2000; 27:2041-2044.
15. Skytta E, Pohjankoski H, Savolainen A. Etanercept and urticaria in patients with juvenile idiopathic arthritis. Clin Exp Rheumatol 2000; 18:533-534.
16. Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359:579-580.
17. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest 2002; 122:1858-1860.
18. The Lenercept Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53:457-465.
19. Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. Lancet 2001; 358:1784.
20. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000; 343:1594-1602.
21. Baert F, Norman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Cohn's disease. N Engl J Med 2003; 348:601-608. This study nicely defines the likelihood of developing idiotypic antibodies and their impact on the therapeutic response.
22. Crandall WV, Mackner LM. Infusion reactions to infliximab in children and adolescents: frequency, outcome, and a predictive model. Aliment Pharmacol Ther 2003; 17:75-84.
23. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. Am J Gastroenterol 2003; 98:1315-1324.
24. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126:19-31. A large study from a major institution.
25. Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. Ann Rheum Dis 2004; 63:156-161.
26. Verea MM, Del Pozo J, Yebra-Pimentel MT, et al. Psoriasiform eruption induced by infliximab. Ann Pharmacother 2004; 38:54-57.
27. Devos SA, van den Bossche N, de Vos M, Naeyaert JM. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. Dermatology 2003; 206:388-390.
28. Foeldvari I, Krüger E, Schneider T. Acute, non-obstructive, sterile, cholecystitis associated with etanercept and infliximab for the treatment of juvenile polyarticular rheumatoid arthritis. Ann Rheum Dis 2003; 62:908-909.
29. Fischer TW, Bauer HI, Graefe T, et al. Erythema multiforme-like drug eruption with oral involvement after intake of leflunomide. Dermatology 2003; 207:386-389.
30. Hansen KE, Cush J, Singhal A, et al. The safety and efficazcy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthr Rheum 2004; 51:228-232.
31. Gómez-Reino JJ, Carmona L, Rodriguez Valverde V, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthr Rheum 2003; 48:2122-2127. This report validates what had been theoretical concerns over TNF-α antagonism and the propensity to develop serious infectious complications. Data from this report support not only the direct impact of these agents on mycobacterial disease, but the increased incidence associated with the underlying disease process.
32. Kwon HJ, Coté TR, Cuffe MS, et al. Case reports of heart after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003; 138:807-811. An important warning of a significant adverse effect. This is all the more compelling in the present lack of predictability of a major complication.
33. Kary S, Burmester GR. Anakinra: the first interleukin-1 inhibitor in the treatment of rheumatoid arthritis. Int J Clin Prac 2003; 57:231-234.
34. Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. Rheumatology 2003; 42:ii29-ii35.
35. Cohen SB, Moreland LW, Cush JJ, et al. A multicenter double-blind randomized placebo-controlled trial of Kineret (anakinra), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate therapy. Ann Rheum Dis 2004; published online first: 13 April 2004 doi: 10.1136/ard.2003.016014.
36. Noga O, Hanf G, Kunkel G. Immunological and clinical changes in allergic asthmatics following treatment with omalizumab. Int Arch Allergy Immunol 2003; 131:46-52. A discussion of the consequences of anti-IgE therapy on the cytokine milieu.
37. Lanier BQ, Corren J, Lumry W, et al. Omalizumab is effective in the long-term control of severe allergic asthma. Ann Allergy Asthma Immunol 2003; 91:154-159.
38. Berger W, Gupta N, McAlary M, Fowler-Taylor A. Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma. Ann Allergy Asthma Immunol 2003; 91:182-188.
39. Holgate ST, Chuchalin AG, Hébert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin Exp Allergy 2004; 34:632-638.
40. Walker S, Monteil M, Phelan K, et al. Anti-IgE for chronic asthma. Cochrane Database Syst Rey 2003; 3:CD003559.